Palbociclib improves patients’ survival in metastatic breast cancer
A Phase III clinical trial has shown that a combination of palbociclib and fulvestrant leads to a longer survival for HR-positive breast cancer...
List view / Grid view
A Phase III clinical trial has shown that a combination of palbociclib and fulvestrant leads to a longer survival for HR-positive breast cancer...
After reviewing numerous studies, researchers from various institutions have identified widespread side effects of drugs on the lungs of patients.
With just under one month until the Drug Supply Chain Security Act is enforced in the US, manufacturers are still not all compliant with the rulings...
Results of a Phae III trial showed that cetuximab with radiation was associated with inferior overall survival and progression-free survival...
Results from a Phase III clinical trial indicate that patients suffering from ankylosing spondylitis could benefit from the biologic drug ixekizumab...
Pharmaceutical service provider relies on expanded capacities, modular production and modern analytics...
Most pharmaceutical companies are now outsourcing work to smaller firms, and here, European Pharmaceutical Review looks at current trends...
Small spectrometry chips could be the future for materials analysis systems, optical coherent tomography in medical imaging and in optical networks...
A market report has given a complete backdrop analysis of the pharmaceutical outsourcing market, including market growth and shares...
Outsourcing has become more popular with pharmaceutical companies, and has led to work being completed quicker, with less effort and cost involved...
Severe asthma sufferers could benefit from newer targeted therapies, and could be identified through levels of periostin in their airways...
The KEYNOTE-048 study examined the use of immunotherapy with pembrolizumab rather than the standard treatment using cetuximab for head and neck cancer...
A 3D bioprinting technique could, in the future, allow the creation of human tissue structures for the analysis of various diseases...
A combination of chemotherapy and immunotherapy could soon be used in NHS hospitals for triple-negative breast cancer to extend patient survival...
A study trialling a short course of trastuzumab in HER2 positive breast cancer patients showed that it is as effective and cheaper than a longer course...